[German] Conclusion of non-exclusive drug rebate agreements according to § 130a Abs. 8 SGB V by means of an open-house model for the active ingredient Perindopril/Amlodipine/Indapamide (WHO ATC code: C09BX01)

This procurement, from Germany and sourced via TED, concerns the conclusion of agreements for pharmaceutical rebates under § 130a Abs. 8 SGB V. The tender focuses on an 'Open-House' model for the active ingredient Perindopril/Amlodipine/Indapamide, specifically excluding existing exclusive discount agreements. The objective is to establish rebate agreements for this combination medication, which is commonly used to treat hypertension. Pharmaceutical procurement of this nature typically involves detailed requirements regarding the product's quality, packaging, and supply chain integrity. Bidders, likely pharmaceutical manufacturers or their representatives, will need to submit proposals for rebate structures based on sales volumes or other agreed-upon metrics. Compliance with German pharmaceutical regulations, including pricing and reimbursement rules, is essential. The 'Open-House' model implies that eligible pharmaceutical companies can join the agreement under predefined conditions, promoting competition and potentially securing cost savings for the contracting health insurance funds or statutory health insurance system.